secwatch.observer — SEC 8-K summary
======================================

Issuer:     Centessa Pharmaceuticals plc (CNTA)
CIK:        0001847903
Form:       8-K
Filed at:   2025-03-24T23:59:59+00:00
Accession:  0001847903-25-000049
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Centessa Q4 net loss widens to $111.3M; cash $482M; OX2R pipeline on track for 2025 data
--------------------------------------------------------------------------------

- Net loss $111.3M in Q4 2024 vs $36.8M Q4 2023, full-year loss $235.8M.
- R&D expenses $60.9M Q4 2024 included $31.5M one-time charge from SerpinPC discontinuation.
- Cash, equivalents and short-term investments $482.2M as of Dec 31, 2024; expected to fund into mid-2027.
- ORX750 Phase 2a CRYSTAL-1 data in NT1, NT2, and IH expected in 2025; Phase 1 data showed restored wakefulness.
- ORX142 and ORX489 advancing in IND-enabling studies with clinical data expected in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847903/000184790325000049/0001847903-25-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847903/000184790325000049/cnta-20250324.htm
  HTML page:      https://secwatch.observer/filing/0001847903-25-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer